チロシンキナーゼ阻害剤市場の評価：結合様式・タイプ・用途・エンドユーザー・地域別の機会および予測（2017年～2031年）

世界のチロシンキナーゼ阻害剤の市場規模は、2024年から2031年の予測期間中にCAGR 7.05％を記録し、2023年の606億米ドルから、2031年には1,045億1,000万米ドルの規模に成長すると予測されています。

チロシンキナーゼ阻害剤の創薬はここ数年で大きく変化しました。新しい薬剤の導入や、癌細胞に対する強力で特異的な増殖阻害剤を作り出す効率的な方法によって、この業界にはいくつかの展望が生まれています。癌の有病率の増加、研究活動の活発化、チロシンキナーゼ阻害剤への投資といった要因が市場の成長を促進すると予想されています。

癌罹患率の上昇は市場成長を促進する主な要因です。中国では2022年に約482万人の新規癌患者が発生し、肺癌がもっとも一般的な癌の種類となっています。同様に、日本では2022年に101万9,000人の新規癌症例が検出され、結腸/直腸癌、胃癌、肺/気管癌、前立腺癌、乳癌がもっとも多いタイプです。癌の罹患率の高さが、癌治療のためのさまざまなチロシンキナーゼ阻害薬の需要を高めています。

政府からの多額の投資がR&D活動への支援を通じて市場を後押ししています。政府機関と研究センターとの協力により、チロシンキナーゼ阻害剤の最新技術開発が大きく進展しています。例えば、NIHが2022年5月に発表したデータによると、米国の癌研究に費やされた金額は、2021年の73億6,200万米ドルから2022年には76億4,400万米ドルに増加しました。

癌の有病率の上昇

癌の有病率の増加は、世界のチロシンキナーゼ阻害剤市場の拡大を大きく後押しすると予想されています。さまざまな種類の癌の有病率が上昇を続ける中、高度で効果的な治療ソリューションに対する需要が高まっています。チロシンキナーゼ阻害剤は、その標的作用機序と副作用の軽減により、癌治療レジメンに受け入れられており、患者とヘルスケア専門家の両方にとって好ましい選択肢となっています。多様な癌タイプを適応症とするための継続的なR&Dが市場成長の推進因子となっています。

チロシンキナーゼ阻害剤のR&Dへの投資の増加

臨床R&Dが世界のチロシンキナーゼ阻害薬市場の成長を牽引しています。癌生物学と新規治療標的の理解に向けた焦点の拡大が市場の拡大に大きく寄与しています。製薬会社や学術機関によるR&D活動への旺盛な投資は市場成長をさらに促進しています。

技術の進歩

遺伝子プロファイルに基づいて個々の患者に合わせた治療を行うことができる精密医療の進歩が世界市場の成長を促進しています。診断技術と遺伝子プロファイリングがより進歩する中で、特定の遺伝子変化を特定する能力が高まり、遺伝子異常に対してより個別化された成功する治療計画が提供されるようになっています。

希少・遺伝性疾患への注目の高まり

希少疾患や遺伝性疾患への注目も世界のチロシンキナーゼ阻害薬市場の成長を牽引しています。標的治療アプローチで知られるチロシンキナーゼ阻害剤は、希少疾患や遺伝性疾患に関連する特定の遺伝子異常に対処する可能性があるとして、その認知度が高まっています。精密医療が注目されるにつれ、これらの疾患特有の遺伝的特徴がより明らかになり、オーダーメイドの治療に対する需要が生じています。

当レポートでは、世界のチロシンキナーゼ阻害剤の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のチロシンキナーゼ阻害剤市場の展望

• 市場規模・予測
• 結合様式別
  • I型阻害剤
  • II型阻害剤
  • III型阻害剤
  • IV型阻害剤
  • V型阻害剤
• タイプ別
  • 非受容体チロシンキナーゼ阻害剤
  • 受容体チロシンキナーゼ阻害剤
  • マルチキナーゼ阻害剤
  • セリン/スレオニンキナーゼ阻害剤
  • プロテインキナーゼC阻害剤
  • RHOキナーゼ阻害剤
  • その他
• 用途別
  • 慢性骨髄性白血病 (CML)
  • 肺癌
  • 乳癌
  • 腎細胞癌
  • その他
• エンドユーザー別
  • 病院
  • 研究センター
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界のチロシンキナーゼ阻害剤市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 結合様式別
• タイプ別
• 用途別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需要供給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• AbbVie Inc.
• Astra Zenca PLC
• Bayer AG
• Boehringer Ingelheim International Gmbh
• Abott Inc.
• Bristol Myers Squibb
• Pfizer Inc.
• Merck & Co., Inc.
• Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Sanofi S A
• Eisai Co. Ltd

第13章 戦略的提言

第14章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 3. Global Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 4. Global Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 5. Global Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 6. Global Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 7. Global Tyrosine Kinase Inhibitors Market Share (%), By Region, 2017-2031F
• Figure 8. North America Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 10. North America Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 11. North America Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 12. North America Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 13. North America Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 14. North America Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
• Figure 15. United States Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 17. United States Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 18. United States Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 19. United States Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 20. United States Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 21. Canada Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 23. Canada Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 24. Canada Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 25. Canada Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 26. Canada Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 27. Mexico Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 29. Mexico Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 30. Mexico Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 31. Mexico Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 32. Mexico Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 35. Europe Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 36. Europe Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 37. Europe Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 38. Europe Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 39. Europe Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 42. Germany Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 43. Germany Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 44. Germany Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 45. Germany Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 46. France Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 48. France Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 49. France Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 50. France Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 51. France Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 52. Italy Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 54. Italy Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 55. Italy Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 56. Italy Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 57. Italy Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 58. United Kingdom Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 60. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 61. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 62. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 63. United Kingdom Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 64. Russia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 66. Russia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 67. Russia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 68. Russia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 69. Russia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 70. Netherlands Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 72. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 73. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 74. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 75. Netherlands Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 76. Spain Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 78. Spain Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 79. Spain Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 80. Spain Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 81. Spain Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 82. Turkey Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 84. Turkey Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 85. Turkey Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 86. Turkey Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 87. Turkey Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 88. Poland Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 90. Poland Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 91. Poland Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 92. Poland Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 93. Poland Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 94. South America Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 96. South America Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 97. South America Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 98. South America Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 99. South America Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 100. South America Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 103. Brazil Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 104. Brazil Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 105. Brazil Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 106. Brazil Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 107. Argentina Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 109. Argentina Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 110. Argentina Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 111. Argentina Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 112. Argentina Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 113. Asia-Pacific Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 115. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 116. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 117. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 118. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 119. Asia-Pacific Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
• Figure 120. India Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 122. India Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 123. India Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 124. India Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 125. India Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 126. China Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 128. China Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 129. China Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 130. China Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 131. China Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 132. Japan Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 134. Japan Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 135. Japan Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 136. Japan Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 137. Japan Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 138. Australia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 140. Australia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 141. Australia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 142. Australia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 143. Australia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 144. Vietnam Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 146. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 147. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 148. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 149. Vietnam Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 150. South Korea Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 152. South Korea Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 153. South Korea Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 154. South Korea Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 155. South Korea Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 156. Indonesia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 158. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 159. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 160. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 161. Indonesia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 162. Philippines Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 164. Philippines Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 165. Philippines Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 166. Philippines Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 167. Philippines Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 168. Middle East & Africa Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 170. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 171. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 172. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 173. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 174. Middle East & Africa Tyrosine Kinase Inhibitors Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 177. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 178. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 179. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 180. Saudi Arabia Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 181. UAE Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 183. UAE Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 184. UAE Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 185. UAE Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 186. UAE Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 187. South Africa Tyrosine Kinase Inhibitors Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Tyrosine Kinase Inhibitors Market, By Volume, In Thousand Units, 2017-2031F
• Figure 189. South Africa Tyrosine Kinase Inhibitors Market Share (%), By Mode of Binding, 2017-2031F
• Figure 190. South Africa Tyrosine Kinase Inhibitors Market Share (%), By Type, 2017-2031F
• Figure 191. South Africa Tyrosine Kinase Inhibitors Market Share (%), By Application, 2017-2031F
• Figure 192. South Africa Tyrosine Kinase Inhibitors Market Share (%), By End-user, 2017-2031F
• Figure 193. By Mode of Binding Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global tyrosine kinase inhibitors market is projected to witness a CAGR of 7.05% during the forecast period 2024-2031, growing from USD 60.6 billion in 2023 to USD 104.51 billion in 2031. Tyrosine kinase inhibitors are regarded as certain enzymes that aid in impeding the growth of malignant cells and the process of cell division as they obstruct the signals that encourage cancer cells to proliferate, these inhibitors are simple to use and helpful in the treatment of cancer patients. Drug discovery for tyrosine kinase inhibitors has changed significantly in the last several years. There have been several prospects for the industry with the introduction of new medications and efficient methods for creating strong and specific growth inhibitors for cancer cells. Factors like the increasing prevalence of cancer, growing research activities, and investment in tyrosine kinase inhibitors are expected to enhance market growth.

The rising incidence of cancer is a major factor driving the market growth. For instance, China experienced approximately 4,820,000 new cancer cases in 2022, with lung cancer being the most common type of cancer. Similarly, in Japan 1,019,000 new cases of cancer were detected in 2022 with colon/rectum cancer, stomach cancer, lung/trachea cancer, prostate cancer, and breast cancer being the most common types. The high incidence of cancers has increased the demand for various tyrosine kinase inhibitor drugs for the treatment of cancers.

Significant investments from the governments have boosted the market through support towards research and development activities. Collaborations between government institutions and research centers have led to significant advancements in developing modern technologies for tyrosine kinase inhibitors. For instance, the amount spent on cancer research in the United States went from USD 7,362 million in 2021 to USD 7,644 million in 2022, according to data released by the NIH in May 2022.

Rising Prevalence of Cancer

The increasing prevalence of cancer is anticipated to significantly boost the expansion of global tyrosine kinase inhibitors market. As the prevalence of various cancer types continues to rise, there is an increasing demand for advanced and effective therapeutic solutions. Tyrosine kinase inhibitors (TKIs) are a crucial class of drugs that have shown remarkable effectiveness in blocking the abnormal activity of tyrosine kinases which are frequently linked to the advancement of cancer. TKIs have gained acceptance in oncology treatment regimens due to their targeted mechanism of action and reduced adverse effects, making them a preferred choice for both patients and healthcare professionals. Ongoing research and development efforts to expand the application of TKIs across diverse cancer indications are driving market growth.

The Indian Council of Medical Research (ICMR) released a bi-annual report in December 2022 that stated the country's average cancer case count for 2022 was 100.4 per 100,000 people, with a high proportion of women (estimated at 105.4 per 100,000) receiving a breast cancer diagnosis. Also, based on data from Cancer Research UK, there were around 17 million new cases of cancer recorded globally in 2018, and by 2040, expected to be over 27.5 million new cases reported globally.

Increasing Investments for Research & Development of TKI

Clinical research and development are driving the growth of global tyrosine kinase inhibitors market due to several factors. The increasing focus on understanding cancer biology and novel therapeutic targets is a significant contributor to the expansion of TKI market. The robust investment in research and development activities by pharmaceutical companies and academic institutions is fostering market growth further.

Clinical trials play a pivotal role in evaluating the safety and efficacy of new TKIs, leading to regulatory approvals and market entry. The continuous exploration of TKIs across diverse cancer indications through well-designed clinical studies enhances their application spectrum and broadens the market's reach. These ongoing trials, confirm the TKI's potential as therapeutics and add to the body of empirical data supporting their clinical usefulness. Furthermore, commercial players, academic institutions, and regulatory agencies are working together to expedite the clinical development process and bring novel TKIs to the markets sooner.

Theseus Pharmaceuticals, Inc., disclosed business and pipeline highlights in August 2022, said to be concentrating on creating next-generation tyrosine kinase inhibitors (TKIs) to develop cancer resistance. Theseus Pharmaceuticals Inc. invested USD 7.3 million in the second quarter of 2022. Therefore, it is anticipated that the market will rise more because of the expanding research efforts and rising investments in tyrosine kinase inhibitors.

Technological Advancements

The advancement of precision medicine is driving the growth of the global tyrosine kinase inhibitors market due to its ability to tailor treatments to individual patients based on their genetic profiles. As diagnostic technologies and genetic profiling become more advanced, the ability to identify specific genetic alterations increases as TKIs are targeted medicines, providing a more individualized and successful treatment plan for genetic defects.

Healthcare practitioners can more accurately match patients to the best TKIs based on their genetic profile due to the growing integration of genomics and molecular diagnostics in cancer care. By specifically targeting cancer cells, it reduces the side effects while still optimizing therapy outcomes. Consequently, the demand for tyrosine kinase inhibitors is expected to increase as precision medicine continues to evolve. Pfizer Inc. was granted approval by the US FDA in March 2021 for a supplemental New Drug Application (sNDA) for the tyrosine kinase inhibitor LORBRENA (lorlatinib), extending its indication to include first-line treatment of patients with non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK). Adults with metastatic NSCLC whose tumors are ALK-positive, as determined by an FDA-approved test, might consider LORBRENA.

Increasing Focus on Rare and Genetic Disorders

The focus on rare and genetic disorders is driving the growth of global tyrosine kinase inhibitors (TKI) market. TKIs, known for their targeted therapeutic approach, are increasingly recognized for their potential to address specific genetic aberrations associated with rare and genetic disorders. As precision medicine gains prominence, the unique genetic signatures of these disorders become more apparent, creating a demand for tailored treatments.

The specificity of TKIs allows for precise targeting of the underlying molecular abnormalities, making them suitable for therapeutic interventions in rare and genetic disorders. Pharmaceutical companies are strategically investing in research and development to explore the applicability of TKIs in these niche markets while driving innovation and expanding the potential use of these inhibitors beyond conventional cancer indications. Moreover, regulatory incentives and orphan drug labels in case of rare diseases create a beneficial environment for market growth.

As healthcare systems and stakeholders increasingly recognize the unmet needs in rare and genetic disorders, the tyrosine kinase inhibitors market is positioned to capitalize on these opportunities, contributing to the advancement of therapeutic options and meeting the specific requirements of patients with these unique conditions. In September 2022, Dizal presented encouraging safety and pharmacokinetic results from the global phase I study of DZD1516 in patients who had relapsed after receiving several prior treatments for HER2 positive metastatic breast cancer (HER2+ MBC). DZD1516 is a HER2 tyrosine kinase inhibitor (TKI) that is intended to be taken orally after being highly selective, powerful, reversible, and fully penetrating the blood-brain barrier (BBB).

North America to Dominate Global TKI Market

North America plays a vital role due to its strong healthcare infrastructure, superior research and development skills, and high cancer prevalence. Tyrosine kinase inhibitors are being developed and commercialized by major pharmaceutical companies, most of which, are situated in North America. For TKIs, North America is dedicated towards innovation and early acceptance of new medicines, and it gives them a responsibility of being the world's most prominent region for oncology.

North America's influential role in research, innovation, and healthcare practices positions it as a key region steering the growth trajectory of global tyrosine kinase inhibitors market. Research centers, academic institutions, and pharmaceutical companies are working together to create an environment that is favorable for clinical trials, which advances the knowledge of TKIs in a variety of cancer types. Moreover, as molecular profiling and genetic testing become standard procedures in cancer care, the increased emphasis on personalized treatment plans and precision medicine in North America will increase demand for TKIs. According to American Cancer Society's data for 2023, about 59,610 new cases of leukemia and 20,380 new instances of acute myeloid leukemia (AML) were reported in the United States. The use of tyrosine kinase inhibitor medication is increasing due to the growing prevalence of cancer cases, which is driving the market in North America.

Future Market Scenario (2024 - 2031F)

As the practice of genetic profiling and molecular diagnosis becomes more popular, the identification of specific gene alterations that cause cancer will become more prevalent, enabling new opportunities for personalized medicine.

Various countries are making significant investments in cutting edge research, clinical trials, and drug discovery contributing to the introduction of new and improved TKIs which in return will help in decreasing the prevalence of lung cancer, breast cancer, chronic myeloid leukemia, and others.

Globally, regulatory bodies from different countries are building frameworks to expedite the development process of inhibitors for oncology. The development of targeted therapies has led to a better understanding of cancer biology, allowing for the identification of more specific drug targets and the development of personalized treatment methods.

Key Players Landscape and Outlook

Leading companies like AbbVie Inc., Astra Zenca PLC, Bayer AG, Boehringer Ingelheim International Gmbh, Abott Inc., Bristol Myers Squibb, Pfizer Inc., Merck & Co., Inc., Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc), F. Hoffmann-La Roche Ltd, Novartis AG, in the kinase inhibitors market have a big influence on the dynamics of the business. These massive pharmaceutical companies are well known for their ongoing commitment towards the development and research of kinase inhibitor. Their impact goes beyond the creation of new products as they actively participate in clinical studies and strategic alliances to increase the use of inhibitors in oncology and other therapeutic areas. These companies are at the forefront of kinase inhibitor therapy innovation and have a significant influence on the market's expansion and future implications for precision medicine and cancer treatment.

The European commission approved the tyrosine kinase inhibitor capmatinib (Tabrecta) in June 2022 as a single treatment for patients with advanced non-small cell lung cancer (NSCLC) with MET exon14 skipping (METex14) altered. These patients need systemic therapy after receiving immunotherapy and/or platinum-based chemotherapy in the past. Merck announced in February 2022 that the European Commission (EC) had authorized once-daily oral TEPMETKO (tepotinib), a tyrosine kinase inhibitor, as a monotherapy for adult patients with advanced non-small cell lung cancer (NSCLC).

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Tyrosine Kinase Inhibitors Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Mode of Binding
  • 4.2.1. Type I Inhibitors
  • 4.2.2. Type II Inhibitors
  • 4.2.3. Type III Inhibitors
  • 4.2.4. Type IV Inhibitors
  • 4.2.5. Type V Inhibitors
• 4.3. By Type
  • 4.3.1. Non-Receptor Tyrosine Kinase Inhibitors
    • 4.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 4.3.1.2. BCR-ABL
    • 4.3.1.3. Janus Kinase (JAK) Inhibitor
    • 4.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 4.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 4.3.1.6. Others
  • 4.3.2. Receptor Tyrosine Kinase Inhibitors
    • 4.3.2.1. VEGFR
    • 4.3.2.2. PDGFR
    • 4.3.2.3. EGFR
    • 4.3.2.4. ALK
    • 4.3.2.5. HER2
    • 4.3.2.6. Others
  • 4.3.3. Multikinase Inhibitors
  • 4.3.4. Serine/Threonine Kinase Inhibitors
  • 4.3.5. Protein Kinase C Inhibitors
  • 4.3.6. RHO Kinase Inhibitors
  • 4.3.7. Others
• 4.4. By Application
  • 4.4.1. Chronic Myeloid Leukemia (CML)
  • 4.4.2. Lung Cancer
  • 4.4.3. Breast Cancer
  • 4.4.4. Renal Cell Cancer
  • 4.4.5. Others
• 4.5. By End-user
  • 4.5.1. Hospitals
  • 4.5.2. Research Centers
  • 4.5.3. Others
• 4.6. By Region
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia-Pacific
  • 4.6.4. South America
  • 4.6.5. Middle East and Africa
• 4.7. By Company Market Share (%), 2023

5. Global Tyrosine Kinase Inhibitors Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Mode of Binding
    • 5.1.2.1. Type I Inhibitors
    • 5.1.2.2. Type II Inhibitors
    • 5.1.2.3. Type III Inhibitors
    • 5.1.2.4. Type IV Inhibitors
    • 5.1.2.5. Type V Inhibitors
  • 5.1.3. By Type
    • 5.1.3.1. Non-Receptor Tyrosine Kinase Inhibitors
    • 5.1.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 5.1.3.1.2. BCR-ABL
    • 5.1.3.1.3. Janus Kinase (JAK) Inhibitor
    • 5.1.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 5.1.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 5.1.3.1.6. Others
    • 5.1.3.2. Receptor Tyrosine Kinase Inhibitors
    • 5.1.3.2.1. VEGFR
    • 5.1.3.2.2. PDGFR
    • 5.1.3.2.3. EGFR
    • 5.1.3.2.4. ALK
    • 5.1.3.2.5. HER2
    • 5.1.3.2.6. Others
    • 5.1.3.3. Multikinase Inhibitors
    • 5.1.3.4. Serine/Threonine Kinase Inhibitors
    • 5.1.3.5. Protein Kinase C Inhibitors
    • 5.1.3.6. RHO Kinase Inhibitors
    • 5.1.3.7. Others
  • 5.1.4. By Application
    • 5.1.4.1. Chronic Myeloid Leukemia (CML)
    • 5.1.4.2. Lung Cancer
    • 5.1.4.3. Breast Cancer
    • 5.1.4.4. Renal Cell Cancer
    • 5.1.4.5. Others
  • 5.1.5. By End-user
    • 5.1.5.1. Hospitals
    • 5.1.5.2. Research Centers
    • 5.1.5.3. Others
  • 5.1.6. United States*
    • 5.1.6.1. Market Size & Forecast
    • 5.1.6.1.1. By Value
    • 5.1.6.1.2. By Volume
    • 5.1.6.2. By Mode of Binding
    • 5.1.6.2.1. Type I Inhibitors
    • 5.1.6.2.2. Type II Inhibitors
    • 5.1.6.2.3. Type III Inhibitors
    • 5.1.6.2.4. Type IV Inhibitors
    • 5.1.6.2.5. Type V Inhibitors
    • 5.1.6.3. By Type
    • 5.1.6.3.1. Non-Receptor Tyrosine Kinase Inhibitors
    • 5.1.6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 5.1.6.3.1.2. BCR-ABL
    • 5.1.6.3.1.3. Janus Kinase (JAK) Inhibitor
    • 5.1.6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 5.1.6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 5.1.6.3.1.6. Others
    • 5.1.6.3.2. Receptor Tyrosine Kinase Inhibitors
    • 5.1.6.3.2.1. VEGFR
    • 5.1.6.3.2.2. PDGFR
    • 5.1.6.3.2.3. EGFR
    • 5.1.6.3.2.4. ALK
    • 5.1.6.3.2.5. HER2
    • 5.1.6.3.2.6. Others
    • 5.1.6.3.3. Multikinase Inhibitors
    • 5.1.6.3.4. Serine/Threonine Kinase Inhibitors
    • 5.1.6.3.5. Protein Kinase C Inhibitors
    • 5.1.6.3.6. RHO Kinase Inhibitors
    • 5.1.6.3.7. Others
    • 5.1.6.4. By Application
    • 5.1.6.4.1. Chronic Myeloid Leukemia (CML)
    • 5.1.6.4.2. Lung Cancer
    • 5.1.6.4.3. Breast Cancer
    • 5.1.6.4.4. Renal Cell Cancer
    • 5.1.6.4.5. Others
    • 5.1.6.5. By End-user
    • 5.1.6.5.1. Hospitals
    • 5.1.6.5.2. Research Centers
    • 5.1.6.5.3. Others
  • 5.1.7. Canada
  • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Mode of Binding
• 6.2. By Type
• 6.3. By Application
• 6.4. By End-user
• 6.5. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Applicable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. AbbVie Inc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Astra Zenca PLC
• 12.3. Bayer AG
• 12.4. Boehringer Ingelheim International Gmbh
• 12.5. Abott Inc.
• 12.6. Bristol Myers Squibb
• 12.7. Pfizer Inc.
• 12.8. Merck & Co., Inc.
• 12.9. Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
• 12.10. F. Hoffmann-La Roche Ltd
• 12.11. Novartis AG
• 12.12. Sanofi S A
• 12.13. Eisai Co. Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us & Disclaimer